LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Biotechnology

Healthcare
$40.06 -1.30%

-$0.39 today

Market cap
$1.30B
Beta
0.71
P/E (TTM)
-21.4
EPS (TTM)
-$1.39
52W Low $13.36High $33.47

Volume 0.36M

Average 0.23M

LBRX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

LB Pharmaceuticals Inc Common StockNASDAQ: LBRX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows 11116.4% year over year

Q1 FY2026 weighted avg shares (diluted) of 28.24M shares rose 11116.4% year over year. Sequentially, it rose 11.6% from the prior quarter. Over 3 fiscal years it compounded at +92.6% a year.

Context

  • Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
28.24M+11.6% QoQ
Last fiscal yearDec 2025
25.3M+614.8% YoY
LTMMar 2026
19.77M— YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11116.4%——
1 year+614.8%——
3-year CAGR+92.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
25.3M USD
Year-over-year change
+614.8%
3-year CAGR
+92.6%

Weighted Avg Shares (Diluted) vs competitors

How LBRX compares with its peers on the latest reported figures

  • LBRX's LTM Mar 2026 weighted avg shares (diluted) of 19.77M shares is the lowest of the 10 companies compared; the peer median is 62.03M shares.
  • Over three fiscal years its annual growth of +92.6% compares with a peer median of +5.5%.
LBRX Competitors Peer median
Weighted Avg Shares (Diluted) for LBRX and competitors
Company Period LTM YoY 3-year CAGR
DNLIDenali Therapeutics Inc.LTM Jun 2026180.46M +5.8%+11.8%
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026173.1M +2.8%+2.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026111.54M +30.4%+42.5%
GHRSGH Research PLCLTM Mar 202662.03M +15.9%+5.5%
MPLTMapLight Therapeutics, Inc.LTM Mar 202643.04M +3.9%+2.0%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202641.9M +115.2%+32.7%
NERVMinerva Neurosciences, Inc.LTM Jun 202635.42M +368.0%+16.6%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 202619.77M —+92.6%
SPTXSeaport Therapeutics, Inc. Common Stock—— ——
Peer median (excluding LBRX) 62.03M+10.2%+5.5%

Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development1.35M7.85M51.17M16.74M
Selling, General & Admin1.46M3.53M13.66M13.66M
Operating Expenses2.81M11.38M64.83M30.4M
Depreciation & Amortization2K4K91K321K
EBITDA(12.19M)(1.45M)(63.01M)(24.88M)
EBITDA Margin————
Operating Income(2.81M)(11.38M)(64.83M)(30.4M)
Operating Margin————
Interest Income73K811K1.72M3.92M
Interest Expense2.15M4.83M00
Other Income / Expenses(11.54M)5.1M1.73M5.2M
Income Before Tax(14.35M)(6.27M)(63.1M)(25.2M)
Pre-Tax Margin————
Income Tax Expense1K1K1K1K
Net Income(14.35M)(6.28M)(63.1M)(25.21M)
Net Margin————
EPS (Basic)(4.05)(1.77)(17.83)(1.00)
EPS (Diluted)(4.05)(1.77)(17.83)(1.00)
Weighted Avg Shares3.54M3.54M3.54M25.3M
Weighted Avg Shares (Diluted)3.54M3.54M3.54M25.3M

LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Intrinsic Alpha fair value

Locked

Current Price

$40.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.